Le renouveau des antagonistes de l'atdostérone [The revived interest in aldosterone antagonists]

Details

Serval ID
serval:BIB_F2AC51DDF1E7
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Le renouveau des antagonistes de l'atdostérone [The revived interest in aldosterone antagonists]
Journal
Revue Médicale Suisse
Author(s)
Waeber B.
ISSN
1660-9379
Publication state
Published
Issued date
2006
Volume
2
Number
78
Pages
2055-2058
Language
french
Abstract
Aldosterone plays a pivotal role in sodium and water homeostasis, in particular in patients with heart failure or high blood pressure. These medications, when used on top of a standard therapy, improve the outcome of patients with heart failure and are also effective in lowering blood pressure of hypertensive patients. The major risk associated with the use of these antagonists is hyperkalemia, which can be prevented in avoiding their prescription in patients with impaired renal function. Eplerenone has the advantage, compared with spironolactone, to be better tolerated in terms of "hormonal" adverse effects.
Keywords
Aldosterone Antagonists, Antihypertensive Agents, Blood Pressure, Drug Therapy, Combination, Heart Failure, Humans, Hypertension, Hypokalemia, Spironolactone, Treatment Outcome
Pubmed
Create date
06/03/2009 13:00
Last modification date
20/08/2019 17:19
Usage data